Skip to content
Triangle logo TriangleGet started
← Study library

NCT02113878 · REGISTRY CONDITION SEARCH

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
COMPLETED
Registry last update
2024-11-05

This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose of Cisplatin

→

outcome · POSTED

Best Overall Response

→

outcome · POSTED

Median Time to Progression

→

outcome · POSTED

24 Month Overall Survival

→

outcome · POSTED

Median Anxiety Score Change

→

outcome · POSTED

Median Depression Score Change

→

outcome · POSTED

P13K Status by Response

→

outcome · POSTED

Maximum Tolerated Dose of BKM120

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent. * Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented SCC of the cervical lymph nodes, with unknown primaries. * \>10 pack years of tobacco use * Age ≥ 18 years * ECOG performance status ≤ 2 * At least one site of measurable disease * Adequate bone marrow function as shown by: ANC \> 1.5 x 109/L, Platelets \>100 x 109/L, Hb \>9 g/dL * Total calcium (corrected for serum albumin) within normal limits * Magnesium ≥ the lower limit of normal * Potassium within normal limits for the institution. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range * Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome) * Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min * Serum amylase ≤ ULN * Serum lipase ≤ ULN * Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L) * Signed informed consent * INR ≤ 2 Exclusion Criteria: * Distant metastatic disease * Less than or equal to 10 pack years of tobacco history * Received prior chemotherapy * Received prior radiation to the head and neck or adjacent anatomical site * Received prior treatment with a P13K inhibitor. * Known hypersensitivity to BKM120 or to its excipients * Acute or chronic liver, renal disease or pancreatitis * Mood disorders ≥ CTCAE grade 3 * Diarrhea ≥ CTCAE grade 2 * Active cardiac disease * History of cardiac dysfunction including any of the following: * Patient has poorly * Impairment of gastrointestinal (GI) function * Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug. * Chronic treatment with steroids or another immunosuppressive agent. * Herbal medications and certain fruits within 7 days prior to starting study drug. * Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Appendix B for a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak inhibitors of CYP3A is allowed). * Undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy. * Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant. * Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. * Known diagnosis of human immunodeficiency virus (HIV) infection * History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    * 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg. * Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43). * Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.
    intervention Names
    1. Drug: BKM120
    2. Drug: Cisplatin
    3. Radiation: Intensity-modulated radiotherapy (IMRT)
    label
    Dose Level 1
    type
    EXPERIMENTAL
  2. description
    * 40 mg BKM120 will be administered orally daily for 45 days. * Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43). * Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.
    intervention Names
    1. Drug: BKM120
    2. Drug: Cisplatin
    3. Radiation: Intensity-modulated radiotherapy (IMRT)
    label
    Dose Level 2
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Dose Level 1
    2. Dose Level 2
    description
    BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
    name
    BKM120
    other Names
    1. Buparlisib
    type
    DRUG
  2. arm Group Labels
    1. Dose Level 1
    2. Dose Level 2
    description
    Cisplatin is a chemotherapy drug
    name
    Cisplatin
    other Names
    1. Platinol-AQ
    2. Platinol
    type
    DRUG
  3. arm Group Labels
    1. Dose Level 1
    2. Dose Level 2
    description
    IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
    name
    Intensity-modulated radiotherapy (IMRT)
    other Names
    1. IMRT
    type
    RADIATION
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
23
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The trial uses 3+3 design to determine maximum tolerated dose (MTD).
    measure
    Maximum Tolerated Dose of Cisplatin
    time Frame
    While on treatment, up to 66 days
  2. description
    The trial uses 3+3 design to determine maximum tolerated dose (MTD).
    measure
    Maximum Tolerated Dose of BKM120
    time Frame
    While on treatment, up to 66 days
secondary Outcomes
  1. description
    The best overall response for each patient is given per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) criteria: Complete Response (CR) - Disappearance of all target and non-target lesions and lymph node short axis is \<10 mm and no new lesions Partial Response (PR) * Disappearance of target lesions and \>=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions or * \>=30% decrease in sum of target lesion diameter and no new lesions Stable Disease (SD) \- Less than 5 mm increase in target lesion diameter unless it results in a \>=20% increase in diameter and \>=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions Progressive Disease (PD) * \>20% increase in target lesion diameter, must be an absolute increase of 5mm or * Substantial worsening in non-target lesion or * New lesion present
    measure
    Best Overall Response
    time Frame
    Measured at end of treatment, up to 66 days
  2. description
    The median amount of time from baseline to progression and/or death. Patients known to be alive at last contact are censored at last contact. All patients alive at 24 months from baseline are censored at 24 months.
    measure
    Median Time to Progression
    time Frame
    Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
  3. description
    The probability of survival at 24 months using Kaplan-Meier estimates. Patients alive at 2 years are censored at 2 years.
    measure
    24 Month Overall Survival
    time Frame
    Up to 24 months
  4. description
    The median change in score on the Generalized Anxiety Disorder - 7 (GAD-7) questionnaire from baseline to cycle 9.GAD-7 has 7 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 21. Higher score represents worse anxiety.
    measure
    Median Anxiety Score Change
    time Frame
    From baseline to cycle 9, up to 66 days.
  5. description
    The median change in score on the Patient Health Questionnaire - 9 (PHQ-8) from baseline to cycle 9. PHQ-9 has 9 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 27. Higher score represents worse depression.
    measure
    Median Depression Score Change
    time Frame
    From baseline to cycle 9, up to 66 days.
  6. description
    Phosphoinositide 3-kinase (PI3K) biomarker status, either positive or negative, analyzed using established methods from tumor biopsies. P13K status is reported by response, either responder (CR or PR) or non-responder (SD or PR).
    measure
    P13K Status by Response
    time Frame
    Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.
Full study description
brief Summary
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
detailed Description
* This phase Ib study is combining standard chemoradiotherapy with weekly cisplatin and BKM120 to assess tolerability of this combination in high risk patients with locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). The investigators will also obtain preliminary information about the efficacy of this treatment. * The participant will receive the study drug buparlisib once daily, by mouth, for 45 days. The participant will be given a study drug-dosing diary for each cycle. It will include special instructions for taking the study drug at home. * The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study before and how well they have tolerated their doses. * All participants will receive weekly cisplatin injection. Cisplatin will be given intra-venously (IV) on days: (1, 8, 15, 22, 29, 36 and 43) at DFCI. * All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks, delivered at DFCI. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. * The investigators would like to keep track of the participant's medical condition. Follow-up will continue every 4 to 12 weeks after the end of treatment for the first year and at the investigator's discretion thereafter.
Source references
references
  1. citation
    Glorieux M, Dok R, Nuyts S. The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. Sci Rep. 2020 Oct 1;10(1):16208. doi: 10.1038/s41598-020-73249-z.
    pmid
    33004905
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-12963173cf7a185eaa8f
      requested nct id
      NCT02113878
      primary nct id
      NCT02113878
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      8db8114df88d87f12875e2414117ad3b9c82e86444e7f0e5ecb305b24fa8943c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-12963173cf7a185eaa8f
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02113878
      occurrences
      1. context exact
        NCT02113878
        end
        11
        exact text
        NCT02113878
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/29/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a10daadd8e61ac74886d8853fa9634fabb74a41f64c5f4965e5218cbde4501ba
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-48212a62b071fc4859d3
      requested nct id
      NCT02113878
      primary nct id
      NCT02113878
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      6b0ccabe779b6690e4ae00f538ccfed7450edaeb81d053ba972b07ebfd44bf55
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-48212a62b071fc4859d3
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02113878
      occurrences
      1. context exact
        NCT02113878
        end
        11
        exact text
        NCT02113878
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/39/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a10daadd8e61ac74886d8853fa9634fabb74a41f64c5f4965e5218cbde4501ba

    Preserved source evidence · Not medical advice